ClinicalTrials.gg

Program

vorolanib

Also written as “EYP-1901”, “CM082” and “CM082 plus JS001”.

Its studies are mostly in Macular Degeneration · Macular Edema · Carcinoma, Renal Cell · Diabetic Retinopathy · Neoplasms, led by 3 companies.

Furthest: phase 3, since Mar 23, 201724 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Betta Pharmaceuticals141 open or runningphase 3since Mar 23, 2017May 22, 2013Jun 2027phase 1 · NCT07809802
EyePoint Pharmaceuticals84 open or runningphase 3since Oct 30, 2024Feb 6, 2021Oct 2027phase 3 · NCT07449923
Tyrogenex20 open or runningphase 2since Jan 21, 2015Feb 14, 2011none ahead

Also a collaborator on its studies: synteracthcr.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Feb 14, 2011.

  1. Oct 15, 2018Phase 2 study in Macular DegenerationBetta Pharmaceuticals · NCT03710863 · 64 enrolled · China
  2. Dec 26, 2018Phase 1 study in Advanced Malignant Solid TumorsBetta Pharmaceuticals · NCT03792958 · 19 enrolled · China
  3. Feb 19, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungBetta Pharmaceuticals · NCT03848611 · 20 enrolled · China
  4. Apr 4, 2019Phase 2 study in Small Cell Lung CarcinomaBetta Pharmaceuticals · NCT03904719 · 30 enrolled · China
  5. Jan 7, 2020Phase 1 study in Myopic Choroidal NeovascularisationBetta Pharmaceuticals · NCT04222842 · 96 enrolled · China
  6. Mar 26, 2020Phase 1 study in Advanced Malignant Solid TumorsBetta Pharmaceuticals · NCT04328506 · 96 enrolled · China
  7. Jun 12, 2020Phase 1 study in Advanced Solid TumorBetta Pharmaceuticals · NCT04434326 · 4 enrolled · China
  8. Feb 6, 2021EyePoint Pharmaceuticals's first study: phase 1 study in Wet Age-related Macular DegenerationNew to EyePoint PharmaceuticalsEyePoint Pharmaceuticals · NCT04747197 · 17 enrolled · United States
  9. May 9, 20222 phase 2 studiesEyePoint Pharmaceuticals · NCT05381948, NCT05383209
  10. Oct 19, 2023Phase 2 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT06099184 · 27 enrolled · United States
  11. Oct 30, 2024Phase 3 study in Wet Age Related Macular DegenerationEyePoint Pharmaceuticals · NCT06668064 · 400 enrolled · United States
  12. Nov 8, 2024Phase 3 study in Wet Age Related Macular DegenerationEyePoint Pharmaceuticals · NCT06683742 · 400 enrolled · United States, Brazil, Czechia and more
  13. Feb 27, 20262 phase 3 studies in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449936, NCT07449923
  14. Sep 3, 2026Phase 1 study in Hepatic Impairment (HI)Betta Pharmaceuticals · NCT07809802 · 36 planned · China

Ahead

  1. Jun 2027Primary completion: phase 1 study in Hepatic Impairment (HI)Betta Pharmaceuticals · NCT07809802
  2. Oct 2027Primary completion: phase 3 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449936
  3. Oct 2027Primary completion: phase 3 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449923

TargetBeta

KDR →read by rule
“Vorolanib, a next-generation vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor (TKI), exhibits unique pharmacodynamic properties that warrant investigation in adjuvant paradigms.”study text, by rule · the study

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
RamucirumabruleEli Lillyphase 358
apatinibruleJiangsu HengRui Medicinephase 347
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07809802Hepatic Impairment (HI) · China1RecruitingBetta PharmaceuticalsJun 202736
NCT07449936Diabetic Macular Edema · United States, Germany, Israel and more3Active, not recruitingEyePoint PharmaceuticalsOct 2027240
NCT07449923Diabetic Macular Edema · United States, Brazil, Czechia and more3Active, not recruitingEyePoint PharmaceuticalsOct 2027240
NCT06683742Wet Age Related Macular Degeneration · United States, Brazil, Czechia and more3Active, not recruitingEyePoint PharmaceuticalsSep 9, 2026400
NCT06668064Wet Age Related Macular Degeneration · United States3Active, not recruitingEyePoint PharmaceuticalsJul 13, 2026400
NCT06099184Diabetic Macular Edema · United States2CompletedEyePoint PharmaceuticalsOct 24, 202427
NCT05383209Nonproliferative Diabetic Retinopathy · United States2CompletedEyePoint PharmaceuticalsFeb 12, 202477
NCT05381948Wet Age-related Macular Degeneration · United States2CompletedEyePoint PharmaceuticalsNov 29, 2023161
NCT04747197Wet Age-related Macular Degeneration · United States1CompletedEyePoint PharmaceuticalsMay 11, 202217
NCT04434326Advanced Solid Tumor · China1CompletedBetta PharmaceuticalsOct 22, 20214
NCT04328506Advanced Malignant Solid Tumors · China1CompletedBetta PharmaceuticalsJul 27, 202096
NCT04222842Myopic Choroidal Neovascularisation · China1SuspendedBetta PharmaceuticalsDec 30, 202196
NCT03904719Small Cell Lung Carcinoma · China2UNKNOWNBetta PharmaceuticalsJun 30, 202130
NCT03848611Carcinoma, Non-Small-Cell Lung · China2UNKNOWNBetta PharmaceuticalsFeb 202120
NCT03792958Advanced Malignant Solid Tumors · China1UNKNOWNBetta PharmaceuticalsJun 202319
NCT03710863Macular Degeneration · China2UNKNOWNBetta PharmaceuticalsJan 1, 202264
NCT03602547Mucosal Melanoma · China2UNKNOWNBetta PharmaceuticalsJul 201940
NCT03286244Advanced Gastric Cancer · China1UNKNOWNBetta PharmaceuticalsAug 201921
NCT03095040Renal Cell Cancer Metastatic · China3UNKNOWNBetta PharmaceuticalsFeb 2021390
NCT02577458Renal Cell Carcinoma Recurrent · China1UNKNOWNBetta PharmaceuticalsMar 201818
NCT02452385Macular Degeneration · China1SuspendedBetta PharmaceuticalsJun 202056
NCT02348359Macular Degeneration · United States2TerminatedTyrogenexDec 12, 2017157
NCT01863485Advanced Cancer · China1CompletedBetta PharmaceuticalsOct 201444
NCT01296581Neoplasms · United States1CompletedTyrogenexJan 201452

How it is read

Names in the registry

  • “EYP-1901”, 8 entries
  • “CM082”, 5 entries
  • “CM082 plus JS001”, 3 entries
  • “vorolanib”, 2 entries
  • “X-82”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.